e Neisseria meningitidis is a human-specific pathogen and leading cause of meningitis and septicemia. Factor H binding protein (fHbp), a virulence factor which protects N. meningitidis from innate immunity by binding the human complement regulator factor H (fH) with high affinity, is also a key antigen in vaccines being developed to prevent meningococcal disease. fHbp can be divided into three variant groups (V1, V2, and V3) that elicit limited immunological cross-reactivity. The interaction of fH with fHbp could impair the immunogenicity of this antigen by hindering access to the antigenic epitopes in fHbp, providing the rationale for the development of nonfunctional fHbps as vaccine candidates. Here, we characterized the two nonfunctional V3 fHbps, fHbp T286A and fHbp E313A , which each contains a single amino acid substitution that leads to a marked reduction in affinity for fH without affecting the folding of the proteins. The immunogenicity of the nonfunctional fHbps was assessed in transgenic mice expressing a single chimeric fH containing domains of human fH involved in binding to fHbp. No differences in anti-V3 fHbp antibody titers were elicited by the wild-type V3 fHbp, V3 fHbp T286A , and V3 fHbp E313A , demonstrating that the nonfunctional fHbps retain their immunogenicity. Furthermore, the nonfunctional V3 fHbps elicit serum bactericidal activity that is equivalent to or higher than that observed with the wild-type protein. Our findings provide the basis for the rational design of nextgeneration vaccines containing nonfunctional V3 fHbps.
N
eisseria meningitidis is a human-specific pathogen and a leading cause of meningitis and septicemia in young children and adolescents worldwide (1, 2) . The bacterium is part of the normal flora of the nasopharynx in 10 to 40% of the population, and colonization generally results in asymptomatic infection (3) (4) (5) (6) . However, occasionally the meningococcus gains access to the bloodstream, where it multiplies rapidly, resulting in severe disease within a few hours of the onset of symptoms. As a consequence, the case fatality rate for meningococcal sepsis remains between 10 and 15%, despite the availability of effective antimicrobials (7, 8) . Capsule-based conjugate vaccines are available against certain serogroups of N. meningitidis (i.e., A, C, Y, and W135) but not against serogroup B strains. The ␣2-8-linked polysialic acid of the serogroup B capsule is identical to a modification on human N-CAM1, resulting in low immunogenicity, and raises concerns about eliciting autoimmune responses if used as a vaccine (9, 10) . Therefore, vaccines are urgently needed for the prevention of serogroup B N. meningitidis, which is the main cause of meningococcal disease in Europe and North America (11) (12) (13) .
Factor H binding protein (fHbp) is a key antigen that elicits protective immunity against N. meningitidis (14) , and it is a major component of vaccines under development (15) (16) (17) (18) . Recently, a multicomponent vaccine containing fHbp (4CMenB or Bexsero) was approved by the European Medicines Agency (19) . fHbp is a 28-kDa surface-anchored lipoprotein that consists of two ␤-barrels connected by a short linker (20) . Based on amino acid alignments, fHbp can be divided into three variant groups (V1, V2, and V3) (14) or two families (A and B) (21) . V1 fHbps are expressed by approximately 60% of invasive meningococcal serogroup B isolates in North America and Europe, while V2 and V3 fHbps are present in around 30% and 10% of the isolates, respectively (22) (23) (24) . Central to vaccine design, immunological crossreactivity between these variant groups is limited, although some cross-reactivity is observed between V2 and V3 fHbps (14, 25) . Furthermore, fHbp binds the negative human complement regulator factor H (fH) at high affinity, with a dissociation constant (K d ) for V1, V2, and V3 fHbps with fH in the nanomolar range (20) . fH is an abundant complement component (26) and the main negative regulator of the alternative complement pathway by acting as a cofactor for factor I cleavage of C3b and by accelerating the decay of the alternative pathway C3 convertase, C3bBb (27) . Recruitment of fH to the surface of N. meningitidis reduces complement activation and promotes immune evasion by the bacterium (28, 29) . fH consists of 20 complement control protein domains (CCPs), and we have shown that CCPs 6 and 7 (fH 6 -7 ) are sufficient for high-affinity interactions between fHbp and fH (20) .
The interaction between fHbp and fH could have consequences for fHbp-based vaccines and affect their efficacy and immunogenicity. As fH engages a large area of fHbp, immunogenic epitopes on fHbp might be hidden. Indeed, several bactericidal monoclonal antibodies (MAbs) raised against fHbp recognize epitopes that include the fH binding site (30) (31) (32) , suggesting that some important epitopes could be concealed when fH is bound to fHbp. Also, downregulation of complement activation by locally recruited fH could impair antibody production, resulting in reduced immunogenicity. These issues would be circumvented by use of nonfunctional fHbps (20) .
Previously, we demonstrated that alanine substitution of two residues (Glu 283 and Glu 304 ) in V1 fHbp results in a marked reduction in affinity with fH (20) . More recently, we undertook extensive alanine substitution of residues in V1, V2, and V3 fHbps that occupy the interface with fH and analyzed the capacity of the proteins to bind fH by surface plasmon resonance (SPR) (33) . This identified a total of 28 fHbps with significantly reduced affinity for fH (K d [dissociation constant] reduced by more than an order of magnitude). Others have identified one V1 (fHbp R106S ) and three V2 fHbps with reduced binding to fH (34, 35) .
As fHbp binds human but not murine fH (36) , the immunogenicity of these fHbps has been assessed in transgenic mouse models. We have assessed the nonfunctional fHbps in mice lacking their endogenous copy of fH and expressing a chimeric fH containing CCP6-8 from human fH to allow binding to fHbp while allowing the remaining domains to perform their regulatory function in their cognate host (33) . Others have used mice harboring an extra human fH transgene in addition to both of their endogenous fH genes (34) . Results demonstrate that nonfunctional fHbps have equivalent or increased immunogenicity compared to the corresponding wild-type proteins (33, 34 land and Wales in January 2008 showed that 16% contain V3 fHbp, which was associated with the same clonal complex (38) . Here, we investigated the nonfunctional V3 fHbp (V3.28; numbering is according to that of http://pubmlst.org/neisseria/) mutants fHbp T286A and fHbp E313A , which were selected based on our mass mutagenesis and binding studies, and their suitability as fHbp-based vaccines was established.
MATERIALS AND METHODS
Expression and purification of recombinant fHbps. Escherichia coli B834 (DE3) containing pET21a, which encodes fHbps, was grown in LB broth base (Invitrogen) containing 100 g/ml carbenicillin (Sigma) at 37°C with shaking at 180 rpm until an absorbance at 600 nm (A 600 ) of approximately 0.6 was reached. To induce expression of recombinant proteins, isopropyl-␤-D-thiogalactopyranoside (IPTG) (Sigma) was added to cultures at a final concentration of 1 mM and were then incubated overnight at 21°C with shaking at 180 rpm. Cells were harvested by centrifugation at 5,000 ϫ g for 30 min at 4°C, washed with phosphate-buffered saline (PBS), and suspended in NPI-20 (50 mM NaH 2 P0 4 , 300 mM NaCl, 20 mM imidazole, pH 8.0) containing protease inhibitors (Roche). Cells were lysed in an EmulsiFlex-C5 homogenizer (Avestin) at 15,000 lb/in 2 . The lysates were centrifuged at 50,000 ϫ g for 30 min at 4°C, and the supernatants were loaded on equilibrated 1-ml HisTrap HP columns (GE Healthcare). Columns were washed with NPI-50 (50 mM NaH 2 PO 4 , 300 mM NaCl, 50 mM imidazole, pH 8.0) and proteins eluted in NPI-300 (50 mM NaH 2 PO 4 , 300 mM NaCl, 300 mM imidazole, pH 8.0). The eluates were dialyzed overnight against 25 mM Tris, pH 8.5, at 4°C and loaded into equilibrated HiTrap Q HP columns (GE Healthcare) using an AKTA system (GE Healthcare). Proteins were eluted in a gradient against 25 mM Tris, pH 8.5, 1 M NaCl, and fractions corresponding to the protein peak were pooled and dialyzed overnight against 50 mM Tris, pH 7.5, 150 mM NaCl at 4°C. fH binding by SPR. Surface plasmon resonance (SPR) was performed using a ProteOn XPR36 (Bio-Rad). Proteins were dissolved in 50 mM sodium acetate (pH 4.5) to a final concentration of 2 M and coupled to the surface of a GLM sensor chip activated with 25% ethyl(dimethylaminopropyl) carbodiimide-N-hydroxysuccinimide (Bio-Rad). To determine the kinetics of the interaction of fHbp with fH, increasing concentrations of fH [6] [7] (from 1 to 16 nM; in 10 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.005% Tween 20, pH 7.5) were injected at 60 l/min for 240 s at 25°C and allowed to dissociate for 1,200 s. The K d (dissociation constant) was determined using ProteOn Manager software (Bio-Rad). To determine antibody binding to fHbps, MAbs were diluted in running buffer to a concentration of 1.5 nM, injected at 60 l/min for 240 s, and allowed to dissociate for 900 s.
ELISAs. Enzyme-linked immunosorbent assays (ELISAs) were performed by coating each well of ELISA plates (Nunc) with 150 ng fHbps overnight at room temperature, which were then blocked with 4% bovine serum albumin (BSA; Sigma) in PBS containing 0.1% Tween 20 (PBS-T) for 1 h at 37°C. To determine binding to fH, full-length fH (Sigma) was added in a dilution series (from 4 g/ml) in 1% BSA in PBS-T (PBS-TB) and incubated for 1 h at 37°C. Plates were then incubated for 1 h at 37°C with polyclonal goat anti-fH immunoglobulin (Quidel) diluted 1:1,000 in PBS-TB and then with horseradish peroxidase (HRP)-conjugated polyclonal rabbit anti-goat immunoglobulin (Dako) diluted 1:5,000 in PBS-TB. To determine MAb binding to fHbp, serial dilutions of MAbs in PBS-TB were added to plates for 1 h at 37°C, which were then incubated with HRP-conjugated polyclonal rabbit anti-mouse immunoglobulin (Dako) diluted 1:5,000 in PBS-TB. To determine antibody titers, serum was added to fHbp-coated plates and incubated for 1 h at 37°C. Plates were subsequently incubated for 1 h at 37°C with HRP-conjugated polyclonal rabbit anti-mouse immunoglobulin (Dako) diluted 1:5,000 in PBS-TB. ELISAs were developed using the DY999 reagents (R&D systems) according to the manufacturer's protocol. Absorbance was measured at 450 nm on a SpectraMax M3 (Molecular Devices).
Far-Western analysis. Proteins (0.5 g) were boiled for 10 min in SDS-PAGE sample buffer and loaded onto 12% SDS polyacrylamide gels. Gels were stained with Coomassie solution or the proteins transferred with a Trans-Blot Turbo system (Bio-Rad) to Immobilon-P membranes (Millipore). Membranes were blocked with 3% (wt/vol) milk solution in PBS-T for 1 h at room temperature and incubated for 1 h at 37°C with normal human serum diluted 1:100 in 1% (wt/vol) milk solution in PBS-T (PBS-TM). Membranes were washed with PBS-T and then incubated for 1 h at 37°C with polyclonal goat anti-fH immunoglobulins (Quidel) diluted 1:1,000 in PBS-TM. After washing with PBS-T, membranes were incubated for 1 h at 37°C with HRP-conjugated polyclonal rabbit antigoat immunoglobulins (Dako) diluted 1:20,000 in PBS-TM. Membranes were washed with PBS-T, and HRP activity was visualized using ECL Western blotting reagent (GE Healthcare) according to the manufacturer's protocol and then exposed to an ECL Hyperfilm (GE Healthcare) for 3 to 5 min.
Assessment of protein stability. Circular dichroism (CD) spectroscopy experiments were performed using a J-815 CD spectrophotometer (Jasco). Proteins were diluted to 0.25 mg/ml in 10 mM phosphate buffer (pH 7.5), 20 mM NaCl, and CD spectra were acquired at 20°C from 200 to 260 nm. For each protein, four spectra were converted into units of ellipticity (), measured in millidegrees (mdeg). Differential scanning calorimetry (DSC) experiments were performed using a MicroCal VP-capillary DSC system (GE Healthcare). Proteins were diluted to 20 M in degassed running buffer (50 mM Tris, 150 mM NaCl, pH 7.5). Proteins and running buffer controls were heated at a rate of 1°C/min from 10 to 110°C. The thermal transition midpoint (T m ) and heat capacity (C p ) were determined using the instrument software (Origin, version 7.0). Trypsin digestion was performed by incubating proteins with trypsin (Sigma) (concentrations, 1,000 ng/ml to 5 ng/ml) for 1 h at 37°C and then analyzed by SDS-PAGE.
Immunization of transgenic mice. The immunogenicity of V3 fHbps was evaluated in C57BL/6 transgenic mice expressing chimeric murine fH containing CCP6-8 from human fH to allow binding to fHbp (33) . Antigens were given by the intraperitoneal route on days 0, 21, and 35, and sera were collected on day 49 by terminal anesthesia and cardiac puncture; on each occasion, mice received 20 g protein in 3 mg/ml alum in 10 mM histidine buffer, pH 6.5, 155 mM NaCl. All procedures with animals were performed according to the United Kingdom Home Office guidelines.
Antigen immunogenicity by serum bactericidal activity (SBA) assay. N. meningitidis M1239 was grown overnight at 37°C in the presence of 5% CO 2 on brain heart infusion (Oxoid) agar plates containing 5% (vol/ vol) horse serum (Oxoid) and suspended to a final concentration of 5 ϫ 10 3 CFU/ml in PBS containing 0.1% (wt/vol) glucose, 0.9 mM CaCl 2 , 0.5 mM MgCl 2 , 12.5% (vol/vol) baby rabbit complement (Cedarlane) and a dilution series of serum from the individual immunized transgenic mice. Control samples were included from which complement or serum was omitted. After incubation for 1 h at 37°C, 10-l samples were plated on BHI agar plates and incubated overnight at 37°C. Colonies were enumerated, and the bactericidal activity was expressed as the reciprocal of the highest dilution of serum that killed more than 50% of the bacteria.
RESULTS AND DISCUSSION
Binding characteristics of modified fHbps. Based on our previous analyses of residues occupying the contact site between V3 fHbp and fH (33), we selected two modified proteins, V3.28 fHbp T286A and fHbp E313A , to establish whether nonfunctional V3 fHbps are suitable as fHbp-based vaccines. The threonine at position 286 is located in the C-terminal ␤-barrel of fHbp and forms a hydrogen bond with lysine 351 in CCP6 of fH. The glutamic acid at position 313 is in the same ␤-barrel and forms a hydrogen bond with a histidine at position 371 on CCP6 of fH (Fig. 1) ; this modified residue corresponds to a reported nonfunctional V2 fHbp (35) . The affinity of fH [6] [7] for the wild-type and mutant proteins was determined by SPR (Fig. 2A) ; both mutants have a marked reduction in affinity. The K d for the wild-type protein was 3.3 Ϯ 0.6 nM but was more than four orders of magnitude higher (146 Ϯ 8 M) for fHbp T286A ; it was not possible to determine the binding constant for fHbp E313A because of its low affinity with fH. These nonfunctional V3 fHbps have lower affinities with fH than with previously characterized V1 proteins (20, 33, 34) , which have K d s between two and three orders of magnitude higher than that of the corresponding wild-type protein. The binding affinities of the reported nonfunctional V2 fHbps (35) were not determined.
Since SPR was performed with fH 6-7 , we next investigated the binding of full-length fH to the wild-type and mutant fHbps by ELISA (Fig. 2B) and far-Western analysis (Fig. 2C) . Both ELISA and far-Western analysis confirmed that fHbp T286A and fHbp
E313A
have reduced capacity to interact with fH. Structural integrity and stability of the nonfunctional fHbps. The impaired binding of nonfunctional fHbps could result from misfolding and/or reduced stability of the antigen, which would be undesirable features for a vaccine. For example, we demonstrated that V2 fHbps are inherently unstable and prone to proteolysis (33) . Furthermore, during analysis of fHbps, we identified a wild-type V3 fHbp that also demonstrates instability (not shown), highlighting the possibility that modification of V3 fHbp results in instability. Therefore, we investigated the folding of the wild-type and mutant V3 fHbps by CD spectroscopy (Fig. 3A) . No differences were observed between the wild-type and mutant proteins, with all three showing the typical ␤-sheet signature, indicated by a single dip in spectra between 200 and 240 nm (39) . Furthermore, we tested the thermal stability of the nonfunctional fHbps by DSC (Fig. 3B) . As previously described (33) , the V3 fHbp wild-type protein unfolded in two transitions, with T m s at 61°C and 84°C, corresponding to the N-and C-terminal ␤-barrels, respectively. Both fHbp T286A and fHbp E313A unfolded in two transitions with similar T m s (61°C and 83°C for fHbp T286A and 64°C and 84°C for fHbp E313A ). Interestingly, the N-terminal ␤-barrel of fHbp E313A appeared to be more stable than that of the wild-type protein (i.e., T m s of 64°C and 61°C for fHbp E313A and the wild-type protein, respectively), which might be explained by Glu 313 interacting with Val 196 in the N-terminal ␤-barrel of fHbp and thereby reducing stability. To investigate local disturbances of the folding of the nonfunctional fHbps, we performed a protease digestion with trypsin (Fig. 3C) . No digestion was observed for either the V3 wild-type or mutant fHbps, indicating that both ␤-barrels of all proteins are intact. In comparison, there is evident degradation of wild-type V1 and V2 fHbps (Fig. 3C) .
Nonfunctional fHbps retain key epitopes. As the modification in fHbp E313A alters the properties of the N-terminal barrel, immunogenic epitopes located in this region might be affected. Therefore, we tested binding of the nonfunctional fHbps against two MAbs which specifically target the N-terminal ␤-barrel of fHbp (Fig. 4) . While binding of MAb 17C1 against V3 fHbp was unaffected by the amino acid substitutions (Fig. 4A and C) , binding of MAb 30G4 to fHbp E313A was reduced when assessed both by SPR and ELISA (Fig. 4B and D) . Similar observations were previously reported for the V2 fHbp E248A mutant, which showed partial loss of binding to a MAb that recognizes epitopes on the N-terminal ␤-barrel (35) . However, as the N-terminal ␤-barrel of V2 fHbps is inherently unstable (33) , any substitution in this barrel might promote instability and thereby reduce both fH and antibody binding.
Immunogenicity of the nonfunctional fHbps.
To determine the immunogenicity of nonfunctional fHbps, transgenic mice expressing chimeric fH were immunized with the wild-type or mutant fHbps, and the immune responses were analyzed. There was no significant difference in anti-V3 fHbp antibody titers in sera from mice immunized with the wild-type or nonfunctional fHbps (Fig. 5A) , indicating that both the wild-type and mutant proteins induce immune responses in the presence of fH and elicit specific antibodies. To determine whether these antibodies are functional, the SBA of the antibodies was investigated against N. meningitidis strain M1239, which expresses the homologous V3.28 fHbp. SBA is a widely accepted correlate of protection against meningococcal disease (40) . Immunizations were conducted on two occasions, and the reciprocal geometric mean SBA titers for both studies are shown in Fig. 5B . Significantly higher SBA titers were obtained for fHbp E313A than for the wild-type protein (P Ͻ 0.05 by two-tailed t test), while fHbp T286A elicited SBAs equivalent to those of the wild-type protein. Interestingly, the equivalent V2 fHbp E248A mutant has been shown to have reduced immunogenicity, albeit in nontransgenic mice, which is likely to reflect instability of this modified V2. In summary, the nonfunctional V3 fHbp antigens that we report here show equivalent or increased immunogenicity compared to wild-type V3 antigens in transgenic mice expressing a chimeric fH which engages the wild-type protein. The protein we modified is closely related to both the antigen in clinical development by Pfizer (i.e., 3.P45; 92% identity) (16) and the gonococcal homologue of factor H binding protein (91% identity), a naturally occurring protein that does not bind factor H (41) . Both of these proteins are immunogenic in mice, while the Pfizer antigen elicits SBA in human volunteers (16) . Our findings provide the basis for the rational design of next-generation fHbp-based vaccines containing nonfunctional V3 fHbp antigens to improve their immunogenicity and strain coverage. Further analysis of the candidates requires evaluation in future clinical trials.
